Anixa Biosciences Clarifies Poster Presentation on Company Website

Rhea-AI Summary

Anixa Biosciences, Inc. (NASDAQ: ANIX) announced a technical error in its website that led to an unrelated poster presentation being displayed on the Corporate Presentations page. The company clarified that the correct presentation of its breast cancer vaccine clinical trial from the 2023 AACR Annual Meeting can be found on the Events page of its website. Anixa focuses on cancer treatment and prevention, collaborating with renowned institutions like Moffitt Cancer Center and Cleveland Clinic for its innovative therapies, including CAR-T technology and vaccines targeting triple negative breast cancer and ovarian cancer.

Positive

• Collaborations with Moffitt Cancer Center and Cleveland Clinic enhance research and development capabilities.
• Focus on innovative cancer therapies, including CAR-T and vaccines, positions Anixa in a growing market.

Negative

• Technical error on the website may affect investor perception and confidence.
• -

SAN JOSE, Calif., April 17, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that a technical error was made by the company's website hosting service provider, causing a poster presentation unrelated to Anixa to be posted on the Corporate Presentations page of the company's website.  The correct presentation of the company's breast cancer vaccine clinical trial from the 2023 AACR Annual Meeting may be found on the Events page of the company's website at https://ir.anixa.com/events.

About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.  Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.  The company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to prevent breast cancer – specifically triple negative breast cancer (TNBC), the most lethal form of the disease – as well as a vaccine to prevent ovarian cancer.  These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.  Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the company to continually examine emerging technologies in complementary fields for further development and commercialization.  To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.

Contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808

View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-clarifies-poster-presentation-on-company-website-301799312.html

SOURCE Anixa Biosciences, Inc.

FAQ

What was the technical error reported by Anixa Biosciences on April 17, 2023?

Anixa Biosciences reported a technical error that caused an unrelated poster presentation to be displayed on their Corporate Presentations page.

Where can I find the correct presentation of Anixa's breast cancer vaccine clinical trial?

The correct presentation can be found on the Events page of Anixa's website.

What are the main focuses of Anixa Biosciences as a biotechnology company?

Anixa focuses on the treatment and prevention of cancer with an emphasis on innovative therapies like CAR-T technology and vaccines.

Which organizations is Anixa collaborating with for its cancer research?

Anixa is collaborating with Moffitt Cancer Center and Cleveland Clinic for its cancer research and development.